Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Keros Therapeutics (KROS) Research & Development (2019 - 2025)

Keros Therapeutics filings provide 7 years of Research & Development readings, the most recent being $17.9 million for Q4 2025.

  • On a quarterly basis, Research & Development fell 60.75% to $17.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $129.6 million, a 25.33% decrease, with the full-year FY2025 number at $129.6 million, down 25.33% from a year prior.
  • Research & Development hit $17.9 million in Q4 2025 for Keros Therapeutics, down from $19.5 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $49.2 million in Q3 2024 to a low of $10.0 million in Q2 2021.
  • Median Research & Development over the past 5 years was $28.0 million (2022), compared with a mean of $29.0 million.
  • Biggest five-year swings in Research & Development: skyrocketed 133.21% in 2022 and later crashed 60.75% in 2025.
  • Keros Therapeutics' Research & Development stood at $18.8 million in 2021, then skyrocketed by 32.04% to $24.9 million in 2022, then soared by 50.77% to $37.5 million in 2023, then rose by 21.71% to $45.6 million in 2024, then crashed by 60.75% to $17.9 million in 2025.
  • The last three reported values for Research & Development were $17.9 million (Q4 2025), $19.5 million (Q3 2025), and $43.5 million (Q2 2025) per Business Quant data.